Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

The French drugmaker said the vaccine it agreed to develop with Johnson & Johnson a year ago was “not sufficiently effective.

The FDA granted approval of Merilog to Sanofi (SNY)-Aventis U.S. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of €120.00. The company’s shares closed last Tuesday at $105.89.

coli disease. Sanofi recorded a $250M impairment charge, lowering Q4 2024 IFRS EPS by €0.15 to €4.44, while business net income and EPS remain unchanged. Get access to your new suite of high ...

Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an invasive form of the digestive pathogen E. coli. Sanofi recorded a $250 ...

The "Sinusitis Pipeline Insight Analysis Report" drug pipelines has been added to ResearchAndMarkets.com's offering.The sinusitis treatment pipeline analysis provides an overview of recent ...

Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by the E.coli bacteria due to a lack of sufficient efficacy, the companies ...

Twenty-two lenders including Citigroup Inc., Goldman Sachs Group Inc. and Morgan Stanley extended an upfront commitment to CD&R last year so the firm could buy part of Sanofi SA’s consumer arm ...

MC: There is no old or new model, but there is old school thinking and open school thinking. We are clearly conscious of this within Sanofi and we truly believe that we will overcome the future ...

Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a U.S. drug ingredients plant tied to its longstanding subsidiary Genzyme.

"Sanofi's collaboration with Exscientia aims to transform how we discover and develop new small molecule medicines for cancer and immune-mediated diseases," said the pharma group's chief ...